American Oncology Network Expands Radiopharmaceutical Therapy Footprint with New Leadership
Event summary
- AON now operates nine active radioligand therapy centers across seven states, with five more in development.
- Robert J. McDonald, MD, FACNM, appointed as radiology medical director and in-house reading radiologist.
- Jason Berilgen, MD, named medical director of radiation oncology to oversee clinical leadership and protocol development.
- AON's radioligand therapy program expanded significantly since its first site launch in 2023 at Genesis Cancer & Blood Institute.
The big picture
AON's expansion reflects the growing trend of bringing advanced cancer treatments closer to patients' communities, reducing travel and improving accessibility. The strategic appointments of physician leaders underscore a focus on clinical excellence and operational support for partner practices. This move positions AON to capitalize on the increasing demand for radiopharmaceutical therapies, a rapidly evolving segment in oncology care.
What we're watching
- Expansion Pace
- The pace at which AON can scale its radiopharmaceutical therapy program while maintaining clinical excellence and operational efficiency.
- Leadership Impact
- How the new physician leaders will influence the strategic direction and execution of AON's advanced oncology services.
- Market Penetration
- Whether AON can sustain its growth trajectory in community oncology by expanding access to innovative cancer treatments.
Related topics